C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Proceedings ArticleDOI
Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
Katherine A. Hoadley,William T. Barry,Brandelyn N. Pitcher,Joel S. Parker,Matthew D. Wilkerson,William J. Irvin,Norah Lynn Henry,Sara M. Tolaney,Chau T. Dang,Ian E. Krop,Donald A. Berry,Elaine R. Mardis,Charles M. Perou,Eric P. Winer,Clifford A. Hudis,Lisa A. Carey +15 more
TL;DR: TP53 mutation is a frequent, clinically important event in HER2-positive disease and predicts pCR to chemotherapy plus Her2-targeting and predicts the total response rate (pCR) regardless of treatment arm.
Proceedings ArticleDOI
Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention.
TL;DR: The key observation is that the fraction of good prognosis tumors substantially increases with age, suggesting thatCurrent screening approaches may not be able to rely on current screening approaches to improve outcomes for young women and those with interval cancers.
Posted ContentDOI
An Integrative Boosting Approach for Predicting Survival Time With Multiple Genomics Platforms
Kin Yau Wong,Cheng Fan,Maki Tanioka,Joel S. Parker,Andrew B. Nobel,Donglin Zeng,Danyu Lin,Charles M. Perou +7 more
TL;DR: This work proposes a variable selection method, termed Integrative Boosting (I-Boost), that makes proper use of all available clinical and genomics data in predicting individual patient survival time and demonstrates that I-Boost provides substantially higher prediction accuracy than existing variable selection methods.
Patent
Methods for typing of lung cancer
TL;DR: In this paper, a method of assessing whether a patient's adenocarcinoma lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) is provided.
Journal ArticleDOI
Rare germline copy number variants (CNVs) and breast cancer risk
Joe Dennis,Jonathan Tyrer,Logan C. Walker,Kyriaki Michailidou,Leila Dorling,Manjeet K. Bolla,Qin Wang,Thomas U. Ahearn,Irene L. Andrulis,Hoda Anton-Culver,Natalia Antonenkova,Volker Arndt,Kristan J. Aronson,Laura E. Beane Freeman,Matthias W. Beckmann,Sabine Behrens,Javier Benitez,Marina Bermisheva,Natalia Bogdanova,Stig E. Bojesen,Hermann Brenner,Jose E. Castelao,Jenny Chang-Claude,Georgia Chenevix-Trench,Christine L. Clarke,J. Margriet Collée,Fergus J. Couch,Angela Cox,Simon S. Cross,Kamila Czene,Peter Devilee,Thilo Dörk,Laure Dossus,A. Heather Eliassen,Mikael Eriksson,D. Gareth Evans,Peter A. Fasching,Jonine D. Figueroa,Olivia Fletcher,Henrik Flyger,Lin Fritschi,Marike Gabrielson,Manuela Gago-Dominguez,Montserrat Garcia-Closas,Graham G. Giles,Anna González-Neira,Pascal Guénel,Eric Hahnen,Christopher A. Haiman,Per Hall,Antoinette Hollestelle,Reiner Hoppe,John L. Hopper,Anthony Howell,Agnes Jager,Anna Jakubowska,Esther M. John,Nichola Johnson,Michael Jones,Audrey Y. Jung,Rudolf Kaaks,Renske Keeman,Elza Khusnutdinova,Cari M. Kitahara,Yon Ko,Veli-Matti Kosma,Stella Koutros,Peter Kraft,Vessela N. Kristensen,Katerina Kubelka-Sabit,Allison W. Kurian,James V. Lacey,Diether Lambrechts,Nicole L. Larson,Martha S. Linet,A. Ogrodniczak,Arto Mannermaa,Siranoush Manoukian,Sara Margolin,Dimitris Mavroudis,Roger L. Milne,Taru A. Muranen,Rachel A. Murphy,Heli Nevanlinna,Janet E. Olson,Håkan Olsson,Tjoung-Won Park-Simon,Charles M. Perou,Paolo Peterlongo,Dijana Plaseska-Karanfilska,Katri Pylkäs,Gad Rennert,Emmanouil Saloustros,Dale P. Sandler,Elinor J. Sawyer,M. P. Schmidt,Rita K. Schmutzler,Rana Shibli,Ann Smeets,Penny Soucy,Melissa C. Southey,Anthony J. Swerdlow,Rulla M. Tamimi,Jack A. Taylor,Lauren R. Teras,Mary Beth Terry,Ian Tomlinson,Melissa A. Troester,Thérèse Truong,Celine M. Vachon,Cam Johnson Wendt,Robert Winqvist,Alicja Wolk,Xiaohong R. Yang,Wei Zheng,Argyrios Ziogas,Jacques Simard,Alison M. Dunning,Paul D.P. Pharoah,Douglas F. Easton +119 more
TL;DR: In this article , rare CNVs in genes and non-coding regions were analyzed for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data.